SU 102
Alternative Names: SU102Latest Information Update: 29 Feb 2008
At a glance
- Originator SUGEN
- Class Antineoplastics
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Feb 2008 Discontinued - Preclinical for Cancer in USA (PO)
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn